Pelage Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for hair loss, including androgenetic alopecia and chemotherapy-induced alopecia. Founded on research from the University of California, Los Angeles (UCLA), Pelage emphasizes a regenerative medicine approach to stimulate hair follicle stem cells. Headquartered in Los Angeles, California, the company is led by CEO Daniel Gil. To date, Pelage has successfully raised substantial funding, including a recent $16.75 million Series A round to further its research and development efforts.
| Attribute | Information |
|---|---|
| Founding Date | 2018 |
| Headquarters | Los Angeles, California |
| Founders | Developed from UCLA research |
| Revenue | N/A |
| Profits | N/A |
| Key Investors | GV, Main Street Advisors, Visionary Ventures, YK BioVentures |
| Industry | Biotechnology |
| Number of Employees | N/A |
Pelage Pharmaceuticals was established in 2018, emerging from groundbreaking research conducted at UCLA. The company's foundation rests on its dedication to using regenerative medicine techniques to combat hair loss. Early research focused on mechanisms to reactivate dormant hair follicles, leveraging small molecules capable of stimulating hair follicle stem cells. Initially, Pelage licensed its intellectual property, including the core molecule PP405, from the UCLA Technology Development Group. This foundation set the stage for aligning scientific innovation with practical application, aiming to provide novel, effective treatment options for various forms of alopecia.
Pelage Pharmaceuticals has grown rapidly due to its focused business model centered around the application of cutting-edge regenerative medicine techniques. Its major achievements include:
As of 2024, Pelage Pharmaceuticals is actively conducting Phase 2 clinical trials for PP405, positioning themselves at the forefront of hair loss treatment innovation. Their approach centers on targeting hair follicle biology directly, offering potentially more effective solutions than existing treatments which often manipulate hormonal pathways. Pelage's focus on non-invasive topical solutions could address a broader patient demographic, spanning various hair and skin types. This strategic differentiation affords Pelage a potentially strong market position, as traditional treatments often have limited efficacy or applicability across a broad audience.
Pelage Pharmaceuticals is at a promising juncture in its journey, poised to make a significant impact in the realm of regenerative medicine for hair loss. By focusing on the reactivation of hair follicle stem cells, Pelage offers a novel approach with the potential for widespread applicability across different hair loss conditions. As they advance through clinical trials and expand their scientific advisory capabilities, Pelage stands out for its commitment to pioneering treatments that bridge innovative research and practical, non-invasive solutions. The company’s trajectory indicates a future where they could redefine standards for hair loss treatments, benefiting diverse populations affected by alopecia.